IP Library Granted Patent US 9,579,329
Granted Patent B2
US 9,579,329 · App. 14/238,310 · Granted Feb 28, 2017

Use of estetrol as emergency contraceptive

Inventors: Wout Wouters (MH Putten, NL); Herman Jan Tijmen Coelingh Bennink (MK Werkhoven, NL); Ludivine Petit (Embourg, BE); Jean-Michel Foidart (Foret Trooz, BE)
Assignee: Estetra S.P.R.L.
A61K31/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,579,329
App. No.
14/238,310
Granted
Feb 28, 2017
Kind
B2
Abstract

The present invention relates to a new use of tetrahydroxylated estrogens such as estetrol (1,3,5(10)-estratrien-3, 15α, 16α, 17β-tetrol), namely in a method of emergency contraception. The method of emergency contraception according to the invention comprises the oral administration of estetrol in a single dose within 120 hours of sexual intercourse.

Claims (16)

1. A method of emergency contraception in a mammalian female

comprising the administration to a female in need of an emergency contraceptive comprising, as the sole active ingredient for inhibiting ovulation and pregnancy, tetrahydroxylated estrogen represented by the general formula (I):

wherein R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group, or an alkoxy group with 1-5 carbon atoms;

wherein each of R5, R6, R7 is a hydroxyl group; and

wherein no more than 3 of R1, R2, R3, R4 are hydrogen atoms, in an effective amount to inhibit ovulation and pregnancy in the female.

2. The method according to claim 1 , wherein said administration is performed through non-vaginal administration.

3. The method according to claim 1 , wherein said administration is performed through oral, parenteral, rectal, transcutaneous or topical administration.

4. The method according to claim 1 , wherein said emergency contraceptive additionally comprises a pharmaceutically acceptable salt of said tetrahydroxylated estrogen or excipient.

5. The method according to claim 1 , wherein said tetrahydroxylated estrogen is estetrol (1,3,5(10)-estratrien-3, 15α, 16α 17β-tetrol).

6. The method according to claim 1 , wherein said emergency contraceptive comprises the tetrahydroxylated estrogen in a dose of between 0.5 and 7 mg/kg, between 1.0 to 5.0 mg/kg, between 1.5 to 2.5 mg/kg, or of about 2.0 mg/kg.

7. The method according to claim 1 , wherein said emergency contraceptive comprises the tetrahydroxylated estrogen in a dose of between 30 mg and 400 mg, between 40 mg and 250 mg, between 40 mg and 200 mg, between 40 mg and 150 mg, between 40 mg and 100 mg, between 50 mg and 100 mg of estetrol, or of about 100 mg.

8. The method according to claim 1 , wherein the administration is performed in a single dosage.

9. The method according to claim 1 , wherein the administration is performed in a double dosage.

10. The method according to claim 1 , wherein said administration is performed within 120 hours after sexual intercourse.

11. The method according to claim 1 , wherein said administration is performed within 96, 72, 48, 24, 12 hours or less after sexual intercourse.

12. The method according to claim 1 , wherein the administration is performed in a double dosage with an interval of 6, 12, 18, or 24 hours.

Assignments (2)
CHANGE OF NAME Recorded Feb 8, 2022
From: ESTETRA S.P.R.L.
To: ESTETRA SRL
Reel/Frame 058978/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2014
From: WOUTERS, WOUT; COELINGH BENNINK, HERMAN JAN TIJMEN; PETIT, LUDIVINE; FOIDART, JEAN-MICHEL
To: ESTETRA S.P.R.L.
Reel/Frame 032962/0667 →
Priority Claims (1)
EP 11177266 · Aug 11, 2011 · regional
Continuity (2)
Provisional Application 61522480 · Aug 11, 2011
Related Publication 20140200202A1 · Jul 17, 2014